A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active:	No
Cancer Type:	Breast Cancer	NCT ID:	NCT04539938
Trial Phases:	Phase II	Protocol IDs:	SGNTUC-025 (primary) NCI-2020-08177
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Seagen Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04539938

Summary

This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan
(T-DXd). It will also look at what side effects happen when these drugs are given together. A
side effect is anything a drug does besides treating cancer.

Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to
other parts of the body (metastatic) or cannot be removed completely with surgery
(unresectable). All participants will get both tucatinib and T-DXd.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.